Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.58 |
| ▸ | REN | P00797 | 2/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | ANPEP | P15144 | 2/20 | 0.55 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.55 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31071616 | 1.00 | DPP3 (0.73) | DPP3OPRM1RENSLC6A2ANPEP | |
| SCHEMBL19787869 | 0.95 | DPP3 (0.69) | DPP3OPRM1RENSLC6A2ANPEP | |
| SCHEMBL31090175 | 0.95 | DPP3 (0.77) | DPP3OPRM1SLC6A2ANPEPLNPEP | |
| SCHEMBL30023454 | 0.91 | DPP3 (0.64) | DPP3OPRM1SLC6A2KISS1R | |
| SCHEMBL29993706 | 0.91 | DPP3 (0.68) | DPP3RENSLC6A2 | |
| SCHEMBL30392261 | 0.90 | DPP3 (0.61) | DPP3OPRM1SLC6A2KISS1R | |
| SCHEMBL31402672 | 0.90 | KISS1R (0.63) | DPP3OPRM1RENSLC6A2KISS1R | |
| SCHEMBL31402666 | 0.88 | AGTR2 (0.61) | DPP3OPRM1RENSLC6A2KISS1R | |
| SCHEMBL30953538 | 0.88 | DPP3 (0.62) | DPP3OPRM1RENSLC6A2 | |
| SCHEMBL30424046 | 0.88 | DPP3 (0.67) | DPP3OPRM1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687942-A1 | DPP3 INHIBITOR FOR MYOCARDIAL PROTECTION AND PREVENTION OF MYOCARDIAL INJURY IN CRITICALLY ILL PATIENTS WITH BLOOD PRESSURE DECLINE | 4TEEN4 Pharmaceuticals GmbH (DE) | 2026-02-11 | — | — | EP | claimed |
| EP-4633659-A1 | DPP3 INHIBITOR FOR IMPROVEMENT OF PULMONARY FUNCTION IN CRITICALLY ILL PATIENTS | 4TEEN4 Pharmaceuticals GmbH (DE) | 2025-10-22 | — | — | EP | claimed |
| WO-2024200862-A1 | DPP3 INHIBITOR FOR MYOCARDIAL PROTECTION AND PREVENTION OF MYOCARDIAL INJURY IN CRITICALLY ILL PATIENTS WITH BLOOD PRESSURE DECLINE | 4TEEN4 Pharmaceuticals GmbH (DE) | 2024-10-03 | — | — | WO | claimed |
| WO-2024126793-A1 | DPP3 INHIBITOR FOR IMPROVEMENT OF PULMONARY FUNCTION IN CRITICALLY ILL PATIENTS | 4TEEN4 Pharmaceuticals GmbH (DE) | 2024-06-20 | — | — | WO | claimed |
| US-20260083672-A1 | FORMULATIONS AND DOSAGE AMOUNTS FOR ADMINISTERING AN ANTI-DPP3 ANTIBODY OR FRAGMENT THEREOF TO HUMANS | 4TEEN4 Pharmaceuticals GmbH (DE) | 2026-03-26 | — | — | US | disclosed |
| EP-4687942-A1 | DPP3 INHIBITOR FOR MYOCARDIAL PROTECTION AND PREVENTION OF MYOCARDIAL INJURY IN CRITICALLY ILL PATIENTS WITH BLOOD PRESSURE DECLINE | 4TEEN4 Pharmaceuticals GmbH (DE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4633659-A1 | DPP3 INHIBITOR FOR IMPROVEMENT OF PULMONARY FUNCTION IN CRITICALLY ILL PATIENTS | 4TEEN4 Pharmaceuticals GmbH (DE) | 2025-10-22 | — | — | EP | disclosed |
| EP-4527458-A2 | DPP3 BINDER DIRECTED TO AND BINDING TO SPECIFIC DPP3-EPITOPES AND ITS USE IN THE PREVENTION OR TREATMENT OF DISEASES / ACUTE CONDITIONS THAT ARE ASSOCIATED WITH OXIDATIVE STRESS | 4TEEN4 Pharmaceuticals GmbH (DE) | 2025-03-26 | — | — | EP | disclosed |
| WO-2025050228-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE OR A COMBINATION OF PEPTIDES AGONISTIC TO THE MAS, AT1 AND AT2 RECEPTORS | PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) | 2025-03-13 | — | — | WO | disclosed |
| US-20240385197-A1 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | 4TEEN4 Pharmaceuticals GmbH (DE) | 2024-11-21 | — | — | US | disclosed |
| CN-118791621-A | DPP3 binding agents directed against and binding to specific DPP3 epitopes and their use in the prevention or treatment of diseases/acute conditions associated with oxidative stress | 4TEEN4制药有限公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024200862-A1 | DPP3 INHIBITOR FOR MYOCARDIAL PROTECTION AND PREVENTION OF MYOCARDIAL INJURY IN CRITICALLY ILL PATIENTS WITH BLOOD PRESSURE DECLINE | 4TEEN4 Pharmaceuticals GmbH (DE) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024126793-A1 | DPP3 INHIBITOR FOR IMPROVEMENT OF PULMONARY FUNCTION IN CRITICALLY ILL PATIENTS | 4TEEN4 Pharmaceuticals GmbH (DE) | 2024-06-20 | — | — | WO | disclosed |
| US-20230295344-A1 | DPP3 BINDER DIRECTED TO AND BINDING TO SPECIFIC DPP3-EPITOPES AND ITS USE IN THE PREVENTION OR TREATMENT OF DISEASES/ACUTE CONDITIONS THAT ARE ASSOCIATED WITH OXIDATIVE STRESS | 4TEEN4 Pharmaceuticals GmbH (DE) | 2023-09-21 | — | — | US | disclosed |
| US-11726094-B2 | Methods for determining DPP3 and therapeutic methods | 4TEEN4 Pharmaceuticals GmbH (DE) | 2023-08-15 | — | — | US | disclosed |
| US-20230213519-A1 | DPP3 IN PATIENTS INFECTED WITH CORONAVIRUS | 4TEEN4 Pharmaceuticals GmbH (DE) | 2023-07-06 | — | — | US | disclosed |
| CN-115769076-A | DPP3 in patients infected with coronaviruses | 4TEEN4制药有限公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-4121763-A1 | DPP3 IN PATIENTS INFECTED WITH CORONAVIRUS | 4TEEN4 Pharmaceuticals GmbH (DE) | 2023-01-25 | — | — | EP | disclosed |
| US-11530276-B2 | DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress | 4TEEN4 Pharmaceuticals GmbH (DE) | 2022-12-20 | — | — | US | disclosed |
| US-20220226446-A1 | NEUROTOXIN COMPOSITIONS FOR USE IN IMPROVING LUNG FUNCTION | BONTI INC (US) | 2022-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083672-A1 | FORMULATIONS AND DOSAGE AMOUNTS FOR ADMINISTERING AN ANTI-DPP3 ANTIBODY OR FRAGMENT THEREOF TO HUMANS | DPP3, DPP4, TREH | DPP3 1/4885OPRM1 1613/4885REN 333/4885 |
| US-11530276-B2 | DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress | DPP3, DPP4, DPP7 | DPP3 1/4885OPRM1 3459/4885REN 226/4885 |
| US-20230213519-A1 | DPP3 IN PATIENTS INFECTED WITH CORONAVIRUS | DPP3, DPP4, DPP7 | DPP3 1/4885OPRM1 2046/4885REN 261/4885 |
| US-20240385197-A1 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | DPP3, DPP4, DPP7 | DPP3 1/4885OPRM1 2816/4885REN 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.